Are Abdominal Aortic Aneurysm Screening Programs Overstated?

With the remarkable drop in tobacco use across the world, also dropped mortality associated to abdominal aorta aneurysm rupture (AAA). All AAA screening programs have been designed decades ago, when the risk was higher. This is why we might need to rethink these programs, or at least design new randomized controlled studies to pave the way.

This Swedish analysis looked into AAA related mortality in the last years and compared men from regions that had access to adequate screening programs and those who did not. Its outcomes raise the question: is it worth to keep systematically screening for this disease?

 

The Swedish program was based on randomized and controlled studies carried out in the 80s and 90s, when the incidence of this disease was higher. Today, some studies account for a 70% drop in AAA incidence, which could be explained by a drop in tobacco use. With the drop in AAA incidence, we could expect a drop in the net clinical benefit of screening programs, or at least a change in their cost benefit ratio.


Read also: Urgent/Emergent TAVR: A Valid Option.


The present study, recently published in the Lancet, looked into AAA related mortality between 1987 and 2015, with a drop from 36 to just 10 deaths every 100,000 men between 65 and 74 years of age.

 

It also compared mortality between regions that had access to these screening programs and those that did not. Mortality decrease after a 6 year follow up saw no changes in the screening group (OR 0.76; CI 95% 0.38–1.51). With today’s figures, for every 10,000 mean actively screened for this disease, we can expect 2 deaths.

 

In the sample group, there obviously were more AAA cases, which lead to 19 programmed interventions every 10,000 hombres, though 49 cases were overdiagnosed.


Read also: Real-Life Functional Assessment of Coronary Stenosis: We Are Yet to Convert to It.


Study limitations include no information on the size or the type or aneurysms and that not all countries had successful stop-smoking programs, so reduced AAA incidence in Sweden does not necessarily mean a global reduction of this disease.

 

Original titleBenefits and harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort study.

Reference: Johansson M et al. Lancet. 2018;391:2441-2447.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...